Cabometyx OverviewCabozantinib, sold under the brand names Cometriq and Cabometyx, is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc. In November 2012, cabozantinib (Cometriq) in its capsule formulation was approved by the U.S. Food and Drug Administration (FDA) under the name Cometriq for treating pa...
Read more Cabometyx Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cabozantinib
Recent Cabometyx Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 20mg, 80mg
- Tablet: 20mg, 40mg, 60mg
NDC Database Records for Cabometyx: (3 results)Sorted by National Drug Code
- 42388-023 Cabometyx 60 mg Oral Tablet by Exelixis, Inc.
- 42388-024 Cabometyx 20 mg Oral Tablet by Exelixis, Inc.
- 42388-025 Cabometyx 40 mg Oral Tablet by Exelixis, Inc.